ELDNMEDIUM SIGNALFINANCIAL10-K

ELDN shows mixed financial signals with significantly reduced operating losses offset by deteriorating cash flow and equity position, alongside a notable 27% share count increase.

The 51% improvement in operating income to -$43M suggests better expense management despite higher R&D spending, but the 32% worsening of operating cash flow to -$62.3M indicates potential timing issues or working capital challenges. The 27% increase in outstanding shares (from 59.9M to 75.9M) combined with 31% decline in stockholders' equity suggests recent equity financing that may have prevented a more severe cash crisis.

Comparing 2026-03-19 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

ELDN's financials present a mixed picture with operating performance improving significantly (operating loss reduced 51% to -$43M) while cash generation deteriorated substantially (operating cash flow worsened 32% to -$62.3M). The company maintained stable cash levels at $22.8M despite higher R&D spending, but stockholders' equity declined 31% to $81.1M while share count increased 27%, indicating dilutive equity financing. Overall, the results suggest a biotech company managing cash burn through equity raises while maintaining R&D investment levels, with improved operational efficiency but ongoing cash flow challenges.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-97%
$565K→$17K

Capex reduced 97% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+58.5%
$11.6M→$18.3M

Current liabilities surged 58.5% — significant near-term obligations; verify ability to meet short-term debt.

Operating Income
P&L
+51.4%
-$88.4M→-$43.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Total Liabilities
Balance Sheet
-45.6%
$59.3M→$32.2M

Liabilities reduced 45.6% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
-31.9%
-$47.3M→-$62.3M

Operating cash flow fell 31.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-31.4%
$118.1M→$81.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
+27.5%
$52.0M→$66.3M

R&D investment increased 27.5% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-26.1%
-$36.2M→-$45.6M

Net income declined 26.1% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+11%
$20.5M→$22.8M

Cash grew 11% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-20
ADDED
As of March 13, 2026 the registrant had 75,851,722 , shares of Common Stock, $0.001 par value per share, outstanding.
Public health crises, including pandemics or epidemics could adversely affect our business.
Our ability to conduct clinical trials in some jurisdictions outside of the United States may be adversely affected' If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.
The compromise of privacy, security, integrity or confidentiality of sensitive information related to our business or failure to comply with confidentiality and data privacy obligations could have a material adverse effect on our business.
Blocking CD40L shifts polarization away from pro-inflammatory signaling to T cell anergy, apoptosis, and polarization to a T-reg environment.
+7 more — sign up free →
REMOVED
A s of March 17, 2025, the registrant had 59,881,775 , sh ares of Common Stock, $0.001 par value per share, outstanding.
Issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities as well as shares and warrants issued or issuable in connection with our recent private placement transactions, could result in significant dilution and could cause our stock price to fall.
If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.
Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development programs or loss of data and have a material adverse effect on our reputation, business, financial condition or results of operations.
We have previously identified and remediated a material weakness in our internal control over financial reporting.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →